Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02980341 |
|
Recruitment Status :
Completed
First Posted : December 2, 2016
Last Update Posted : December 15, 2023
|
Sponsor:
Daiichi Sankyo Co., Ltd.
Collaborator:
Daiichi Sankyo
Information provided by (Responsible Party):
Daiichi Sankyo ( Daiichi Sankyo Co., Ltd. )
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | August 16, 2021 |
| Actual Study Completion Date : | September 7, 2023 |
| Certification/Extension First Submitted : | July 18, 2022 |